

Toward Targeted ECT

van Diermen, Linda; Poljac, Ervin; Van der Mast, Roos; Plasmans, Kristiaan; Van den Aemele, Seline; Heijnen, Willemijn; Birkenhäger, Tom; Schrijvers, Didier; Kamperman, Astrid

Published in:
The Journal of Clinical Psychiatry

DOI:
[10.4088/JCP.20m13287](https://doi.org/10.4088/JCP.20m13287)

Publication date:
2020

License:
Unspecified

Document Version:
Accepted author manuscript

[Link to publication](#)

Citation for published version (APA):
van Diermen, L., Poljac, E., Van der Mast, R., Plasmans, K., Van den Aemele, S., Heijnen, W., Birkenhäger, T., Schrijvers, D., & Kamperman, A. (2020). Toward Targeted ECT: The Interdependence of Predictors of Treatment Response in Depression Further Explained. *The Journal of Clinical Psychiatry*, 82(1), [20m13287]. <https://doi.org/10.4088/JCP.20m13287>

Copyright

No part of this publication may be reproduced or transmitted in any form, without the prior written permission of the author(s) or other rights holders to whom publication rights have been transferred, unless permitted by a license attached to the publication (a Creative Commons license or other), or unless exceptions to copyright law apply.

Take down policy

If you believe that this document infringes your copyright or other rights, please contact openaccess@vub.be, with details of the nature of the infringement. We will investigate the claim and if justified, we will take the appropriate steps.

Towards targeted ECT

The interdependence of predictors of treatment response in depression further explained

Linda Van Diermen^{#,a,b,c}, MD, PhD

Ervin Poljac^{a,b}, PhD

Roos Van der Mast^d, MD, PhD

Kristiaan Plasmans^c, MD

Seline Van den Aemele^{a,b,e}, MD, PhD

Willemijn Heijnen^f, MD

Tom Birkenhäger^f, MD, PhD

Didier Schrijvers^{a,b}, MD, PhD

Astrid Kamperman^g, PhD

= Early Career Psychiatrist

Affiliations

^a University Psychiatric Center (UPC) Duffel. Stationsstraat 22c, 2570 Duffel, Belgium.

^b Collaborative Antwerp Psychiatric Research Institute (CAPRI), Faculty of Medicine and Health Sciences, University of Antwerp. Universiteitsplein 1, 2610 Antwerp, Belgium.

^c Psychiatric Center Bethanië. Andreas Vesaliuslaan 39, 2980 Zoersel, Belgium

^d Department of Psychiatry, Leiden University Medical Center. Albinusdreef 2, 2333 ZA Leiden, The Netherlands.

^e Department of Psychiatry, University Hospital Brussels (UZ-VUB), Laarbeeklaan 101, 1090 Brussels, Belgium.

^f Department of Psychiatry, Erasmus MC, University Medical Center Rotterdam. Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.

^g Epidemiological and Social Psychiatric Research Institute (ESPRi), Department of Psychiatry, Erasmus University Medical Centre. Doctor Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands

Funding/support: None.

Potential conflicts of interest: The authors report no financial or other relationship relevant to the subject of this article.

Corresponding author: Linda van Diermen, MD, PhD. PC Bethanië, Andreas Vesaliuslaan 39, 2980 Zoersel. T +32 3380 3011. E-mail: linda.van.diermen@emmaus.be.

Abstract and keywords

Objective

Several clinical variables assumed to be predictive of electroconvulsive therapy (ECT) outcome in major depression show substantial interrelations. In the current paper we try to disentangle this interdependence to distil the most important predictors of treatment success to help improve patient-treatment matching.

Methods

We constructed a conceptual framework of interdependence capturing age, episode duration, and treatment resistance, all variables associated with ECT outcome, and the clinical symptoms of what we coin 'core depression', i.e., depression with psychomotor agitation, retardation, or psychotic features, or a combination of the three. The model was validated in a sample of 73 patients with a depressive episode according to DSM-5 treated with ECT (August 2015 – January 2018) using path analyses, with the size and direction of all direct and indirect paths being estimated using structural equation modelling. Reduction in Montgomery-Asberg Depression Rating Scale (MADRS) scores during treatment was taken as ECT outcome measure.

Results

The baseline presence of psychomotor agitation, retardation, and/or psychotic symptoms strongly correlated with beneficial ECT outcome ($z=.85$ (se: .17); $p<0.001$). The association between age and the effect of ECT appears to be mediated by their presence ($z=.53$ (se: .18); $p<0.001$). There was no direct correlation between age and ECT response ($p=.478$) but there was for episode duration ($z=-.38$ (se: .08); $p<0.001$).

Conclusion

ECT is a very effective treatment option especially for patients suffering from severe depression characterized by the presence of psychomotor agitation, psychomotor retardation, psychotic symptoms, or a combination of these three features, with the chance of a beneficial outcome being reduced in patients with a longer episode duration. Age may have been given too much weight in ECT decision making.

ClinicalTrials.gov: Identifier: NCT02562846.

Keywords

Electroconvulsive therapy, depression, prediction, psychotic, psychomotor, age.

Introduction

Electroconvulsive therapy (ECT) is a very effective treatment for severe major depressive disorder (MDD) ^{1,2}. Given its effectiveness, especially in the most severe cases ³, its relatively fast onset of action compared to antidepressants ⁴, and the ease of monitoring adherence to treatment, ECT has become indispensable in today's clinical practice. Still, a more targeted use of ECT could further increase its efficacy and limit exposure to the treatment and its side effects for those less likely to benefit (fully) from it. In the light of the demand for value-based health-care delivery, this would improve the economic sustainability of our health-care systems ⁵. The current paper focuses on easy-to-assess clinical variables associated with a positive outcome of ECT.

In a recent meta-analysis ⁶, longer episode duration and medication failure were associated with reduced efficacy of ECT in patients with MDD. In our 2018 meta-analysis of clinical predictors we concluded that ECT was most successful in older patients and those with more severe depression and psychotic features ³. We recently reported that the presence of psychomotor symptoms such as retardation (noticeable manifestations of slowing) and agitation (increased activity) also appears to be closely related to ECT outcome in depression: the patients with evident psychomotor symptoms were 4.9 times more likely to respond to ECT than those not presenting with such symptoms ⁷.

Psychomotor symptoms are a typical characteristic of melancholic depression ^{8,9}, with the symptoms often being more pronounced in depressed patients with psychotic features ^{9,10}. From a clinical point of view, patients with melancholic and/or psychotic depression are treated with ECT relatively early on in their disease, while patients without these symptoms have usually been treated with several antidepressants before ECT is considered, thereby prolonging the duration of the depression and increasing the risk of treatment resistance. Some of the clinical factors that have been linked to ECT outcome, more specifically age, episode duration, and resistance to antidepressant treatment, may therefore have their predictive effects mediated by these psychomotor and psychotic symptoms.

Recently, a path model proposed by Heijnen *et al*¹¹, showed that age exerted its predictive effect on ECT outcome via other clinical variables, among which were psychomotor retardation and psychotic symptoms¹¹. It has remained unclear whether episode duration and treatment resistance are independent predictors or whether the predictive effect of one is confounded by the presence of other factors. We consequently wondered how these predictors relate to each other and to ECT outcome.

We decided to extend the Heijnen *et al* model by taking into account all the clinical predictors that have been shown to be relevant in past meta-analyses. The proposed new model utilizes more precise evaluation scales to assess the two key elements, i.e., psychomotor and psychotic symptoms. In our conceptual model (Figure 1), we suggest that ECT outcome is primarily related to the presence of a depression with psychomotor retardation, agitation, or psychotic features, or a combination of these symptoms. We propose to describe a depression with the above-mentioned features as '*core depression*'. We chose not to use the term melancholic depression with/without psychotic symptoms because the depression construct we describe is based on a selection of symptoms. The other factors that have been linked to ECT outcome are hypothesized to be indirect predictors, whose effects are mediated by the presence of elements of core depression.

<Insert figure 1 approximately here>

Methods

Study group

We designed a *single-site* prospective observational study for patients with a depressive disorder that were treated with ECT. The study was registered in the online clinical database ClinicalTrials.gov (Identifier: NCT02562846). Patients were included between August 2015 and August 2017. The study was approved by the Ethics Committee of the University Hospital of Antwerp. For a detailed description of the study methodology, we refer to several other papers describing our PROTECT cohort ^{7,12,13}.

To be eligible for study inclusion, patients had to meet the following criteria:

- Having been admitted to the University Psychiatric Hospital in Duffel (Belgium) or consulting for outpatient treatment with ECT.
- A diagnosis of major depressive disorder (MDD) or major depressive episode (MDE) in bipolar disorder (according to DSM-5 criteria, as determined during the MINI interview¹⁴ at screening) and a baseline Hamilton Depression Rating Scale-17 items (HDRS-17)¹⁵ score ≥ 17 with an indication for ECT.
- Age between 18 and 85 years.

Patients meeting one or more of the following criteria were excluded from the study:

- Having a drug or alcohol dependence (<6 months before ECT), or a primary psychotic disorder as determined during the MINI interview¹⁴ at screening.
- Being currently enrolled in a study with an investigational study drug.
- Any other condition that, in the opinion of the investigator, would compromise the wellbeing of the participant or prevent him/her from meeting or performing the study requirements.

All patients scheduled for treatment with ECT in our hospital were screened for inclusion in our study and, when eligible, asked for their informed consent.

Treatment

Electroconvulsive therapy

Patients were treated with ECT twice a week using a brief-pulse (0.5ms) constant-current Thymatron IV system (Somatics LLC, Lake Bluff, Illinois, USA). Electrodes were placed right unilaterally (RUL), bilateral electrode placement was used when a fast antidepressant effect was needed¹⁶. Patients that were initially treated with RUL ECT were switched to bitemporal ECT if response was inadequate after six treatments. Etomidate was the anesthetic of choice (0.15mg/kg). Propofol (1mg/kg) and ketamine (1-2mg/kg) were used when etomidate was not tolerated or when clinical response was lacking after the first 12 sessions, respectively. Succinylcholine (0.5mg/kg) was the muscle relaxant used. Lithium and benzodiazepines were withheld at least 12 hours before each session given the negative influence of lithium on cognitive functioning¹⁷ and benzodiazepines on seizure duration¹⁸. The stimulus dose was established prior to the first session by the age method for RUL electrode placement and half-age method for bilateral electrode placement¹⁹. After two sessions with insufficient seizure quality or duration despite adaptations for the potential influence of psychotropics / anaesthetics, retitration was performed (dose increase with 50%).

The endpoint of the ECT course was determined by the treating psychiatrist based on improvement of mood as well as side effects of the treatment. ECT was continued until intolerable side-effects or remission of depressive symptoms occurred. Treatment was also stopped when patients showed no further improvement during the last three sessions.

Pharmacological

Seven percent of patients did not use any antidepressant before ECT. Seventy-four percent of patients was treated with antidepressant monotherapy (most often tricyclic antidepressants (n=38)) and selective serotonin reuptake inhibitors (n=12)) and 19% with a combination of antidepressants. Almost eighty percent of patients used additional antipsychotics for psychotic symptoms or agitation; 27% was on add-on mood stabilizers (mainly lithium) and benzodiazepines were used in up 73% of patients (on average, 8.5(±5.9) mg diazepam equivalents/day). Patients continued pharmacological treatment during the study period, with the drugs and doses preferably not being changed four weeks before and during the ECT course.

Predictors of ECT outcome

We considered those variables that have been most consistently found to be associated with ECT outcome^{3,6,7}. **Age** was considered as a continuous variable. **Psychomotor functioning** was assessed with the CORE assessment of psychomotor functioning and patients were classified as either melancholic or not melancholic based on a CORE cut-off score of 8^{20,21}. To get an indication of the content of the psychomotor symptoms, the continuous scores on the CORE agitation and retardation subscales were used. **Psychotic symptoms** were either classified as present or absent; their severity was assessed using the psychosis subscale of the Psychotic Depression Assessment Scale (PDAS)^{22,23}. **Episode duration** was used as a continuous variable (in months), but also dichotomized: < 6 months or ≥ 6 months). Treatment resistance was also dichotomized based on whether patients had either received 0-2 or >2 adequately dosed but failed antidepressant treatments of adequate duration for the current depression.

Definition of treatment outcome

The reduction in MADRS scores during treatment was used to quantify the effect of the ECT intervention. The MADRS is a scale that is rather sensitive to change²⁴ and independent of the presence and severity of psychomotor functioning. The primary outcome measure was the reduction of the actual MADRS score. In an attempt to isolate the mood effect, change in MADRS dysphoria factor (consisting of the items reported sadness, pessimistic thought, suicidal thought – to isolate the mood effect) was computed^{25,26} and used as a second outcome variable.

Statistical analysis

Pearson or Spearman correlations were computed for variables coding for age and episode duration, treatment resistance, depressive symptomatology (i.e., psychotic features, psychomotor agitation, and psychomotor retardation), and treatment outcome. To estimate the mediating role of depressive symptoms in the relationship between age / episode duration / treatment resistance, and ECT

treatment effect, we constructed a path model and estimated the size and direction of all direct and indirect paths using structural equation modelling. For this purpose, we used the presence of psychotic symptoms and the severity of psychomotor agitation and retardation to create a latent variable, which we termed 'core depression'.

Finally, by means of sensitivity analysis, we re-estimated our path model, alternately using the dichotomized variable for episode duration instead of a continuous variable, treatment resistance instead of episode duration, a dichotomous variable to code for the presence or absence of CORE-defined melancholia instead of two continuous variables coding for agitation and retardation, the PDAS psychosis subscale score to code for the severity of psychotic symptoms instead of the presence/absence of psychotic symptoms, and the absolute change in MADRS dysphoria factor instead of the change in total MADRS score, separately.

We used the following categories for our interpretation of the strength of the path coefficients: weak (<0.2), moderate (0.2–0.5) or strong (>0.5)²⁷. Since our model included both continuous and dichotomous variables, SEM analyses were conducted using robust weighted least squares estimation²⁸. The fit of the path models is described using Chi-square test and p-value (a non-significant Chi-square test indicates little difference between expected and the observed covariance matrices), the Comparative Fit Index (CFI; acceptable fit is indicated by a value ≥ 0.90 ²⁹), and the Root Mean Square Error of Approximation (RMSEA; a value ≤ 0.08 indicates good fit³⁰). Additionally, we report the R-square of the observed (treatment effect) and latent (core depression) outcome variables. The path analysis was conducted using MPlus, version 7.4³¹.

Results

We screened 120 patients diagnosed with MDD or MDE scheduled for ECT between August 1, 2015, and September 1, 2017. Forty-seven patients were not included for different reasons (see Figure 2). The 73 patients participating in the study all gave their informed consent.

<Insert figure 2 approximately here>

The reasons for screening failure (N=16) were diverse. Three patients were too severely depressed to participate, mostly because of catatonic episodes during which they did not speak or interact with caregivers. One patient did not speak Dutch and two were excluded because of recent (<6 months) alcohol and/or cannabis dependency. The remaining 10 patients were excluded because of various diagnostic issues.

The clinical characteristics of the final patient sample can be found in Table 1. Our cohort was characterized by a relatively long mean episode duration and a clear predominance of female patients.

<Insert table 1 approximately here>

The results of the path analysis (Table 2 and Figure 3) show that the presence of core depression is strongly associated with change in depressive symptoms following an ECT course. The association between age and the effect of ECT appears to be mediated by the presence of core depression. There is no direct association between age and the effect of ECT. Episode duration only has a direct association with ECT outcome. The model fit is acceptable.

<Insert table 2 and figure 3 approximately here>

Correlations between the variables used in the path model can be found in Supplementary Table 1 and the results of the sensitivity analyses in Supplementary Tables 2 to 6. In most cases, the (dichotomous or continuous) variable changed in the analysis did not appear to greatly influence the size and significance of the associations. Because episode duration and treatment failure correlated strongly, they were not both incorporated in our original model. Having replaced episode duration by treatment resistance in one of the sensitivity analyses, we found that, unlike episode duration, treatment resistance was not directly associated with ECT outcome. In another sensitivity analysis, we

used the dichotomous version of psychomotor symptoms in general ($CORE < \text{or} \geq 8$) instead of the clinically relevant split-up of agitation and retardation, but although the fit of this alternative model is better, this rather robust dichotomous variable did not markedly change the associations found in the path models.

Discussion

In this paper we evaluated the interdependence of a literature-based selection of clinical predictors of ECT outcome in a Belgian cohort using a path model. Compared to the model recently proposed in a study conducted in The Netherlands ¹¹, we included an extra variable (episode duration) and grouped the psychomotor (retardation and agitation) and psychotic variables under the term core depression (Figure 1). We found a direct association between the presence of core depression and ECT response. Contrary to the results of previous meta-analyses, we did not find a direct predictive effect of age. Rather, the influence of age appeared to be mediated by the presence of symptoms of a core depression.

Both psychomotor retardation and the presence of psychotic symptoms were associated with ECT outcome in both the Dutch and the Belgian cohort, while we, contrary to the Dutch study, also found presence of agitation to be associated with increased effectiveness of ECT. An explanation for this difference could be that, where Heijnen *et al* (2019) used HDRS item scores, the CORE agitation subscale we employed appears more sensitive in detecting the presence of agitation. Age was only indirectly associated with ECT outcome in both cohorts. We hence hypothesize that, rather than being a consequence of aging in and of itself, the favorable response ensues from clinical factors that distinguish older from younger patients ³². A better response to ECT in an older population might then be related to a higher incidence of psychotic depression ^{33,34} and a higher severity of psychomotor agitation or retardation ^{35,36} relative to what is generally observed in younger patients, rather than to age per se.

This is a fundamental finding, putting results of other studies and our own meta-analysis summarizing these studies³ into perspective. Our meta-analysis of results obtained in over 2800 patients confirmed the superior effect of ECT in older patients. The heterogeneity among the studies evaluated could not be explained by the presence of psychotic symptoms, but records of this potentially influential factor were not available for all studies. Contrary to what we then posed, i.e., to have age as one of several elements guide the choice for ECT, the present more detailed look at the interdependence of the outcome predictors leads us to reconsider this statement. We now venture that in the past decades age has been given too much weight in the decision whether or not to prescribe ECT.

Episode duration, on the other hand, was directly associated with ECT response. Several factors can cause episodes to be prolonged, such as late help-seeking³⁷, prior inadequate treatment³⁸, or prior nonresponse to adequate treatment³⁹. The fact that a patient with MDD or MDE does not respond to a sequence of adequate medication regimens might suggest that we are dealing with a treatment-resistant depression, although inadequate diagnostics³⁸, the presence of comorbidity⁴⁰, or other factors, such as familial, social, financial, or employment issues, may have prevented (full) recovery as well. When depressive symptoms persist, it is more likely that patients will encounter more of these additional problems, further delaying or reducing the chance of recovery. Accordingly, we speculate that the association between episode duration and ECT outcome could also be mediated by factors that we did not evaluate in our present investigations, such as the presence of a personality disorder⁴¹⁻⁴³.

Our path model has a reasonable fit and its validity is also confirmed by several sensitivity analyses. The model with CORE-defined melancholia as a dichotomous variable is a better fit to our data than our original model. We do however choose to retain and put forward the original model, based on theoretical and clinical grounds. Also, the original model gives us more information about how the variables relate to each other, which is the focus of these analyses.

The identification of reliable predictors of ECT response in depressive disorder can contribute to a more targeted patient selection, enhancing outcomes and remission rates, and thereby limiting the burden of depression for both the patient and society. A more critical consideration of its application in patients not likely to respond would limit the burden of ECT. In view of the demand for budget cuts in health care and the severity of the pathology in the patient populations typically treated with ECT, low-cost and quick assessment strategies are preferred over expensive and more invasive testing such as brain imaging. In our search for clinician- and patient-friendly assessment tools, we evaluated the predictive capacity of several relevant and easy-to-assess clinical variables, thereby offering a practical, cost-effective solution for a more accurate patient-treatment matching.

At the end of this discussion we speculate about the reason that psychomotor and psychotic symptoms are more frequently present in the older patients in our sample. Depression in older adults can be difficult to recognize, because the symptoms are often attributed to ageing itself, poor health or dementia. The elderly seem to have a tendency to under-report depressive symptoms. One could expect gradual worsening of symptoms if a depressive disorder is not recognized, eventually resulting in more severe forms of depression with psychomotor and psychotic symptoms. The consequences of depression with psychomotor and psychotic symptoms (reduced intake, insomnia, severe psychomotor retardation) in the frail older patient could soon be more profound because of limited reserves. While patients in midlife can often be successfully treated with antidepressants in an ambulatory setting, the threshold for hospitalisation seems to be and should be lower for older patients. Looking at

treatment of depression, pharmacotherapy in the elderly is more complicated than in younger patients because elderly are prone to side-effects and encounter more difficulty tolerating doses in the therapeutic range. Also, it is known that elderly respond somewhat slower to antidepressant drugs than do younger patients. In our centre, ECT is suggested relatively soon for this vulnerable patient group, as long delays could be life-threatening.

Strengths and limitations

This is one of the first studies to look at the interdependence of several typical ECT outcome predictors rather than at the predictive effect of separate variables. Building on the first study to do so, we extended the conceptual model proposed by our Dutch colleagues¹¹ and used more sensitive scales to identify the presence and quantify the severity of the various predictors, which we feel are major strengths of our study. The use of sensitivity analyses enabled us to confirm our findings in our own cohort, while the naturalistic design of our study also is an advantage since, by testing it in a 'real-world' population of severely depressed patients receiving treatment with ECT, it shows the potential of our model for use in clinical practice.

We have used the intention-to-treat sample (N=73) in our analyses to limit the risk of overestimation of effect and path sizes. The true path sizes may therefore be even more pronounced than we calculated. Also, using the intention-to-treat sample makes our model better translatable to clinical practice. The relatively small sample size could be considered a limitation of our study and requires replication of our findings in a larger sample. This could be of great value to validate our findings and extend the evidence on what seems to be a rather commonsense finding – that the symptom profile of the depressed patient determines whether or not they will respond to ECT.

We opted for a conceptual model using -a container construct- of symptoms of clinical depression with a focus on psychotic and psychomotor symptoms, because, theoretically, this seemed the most plausible approach to our query. This could lead to the misinterpretation that in order to consider ECT one should look for a specific subtype of depression, while based on our analyses we can only conclude that presence of the separate elements of the container construct is associated with ECT outcome. One could also argue that this model is not complete, that alternative models should also be tested. For example, we considered taking psychotic symptoms out of our container construct to gain further insight into the other variables' interdependence. We hope further data collection will shed more light on how all the different elements determining ECT response in patients with severe depression interact.

Episode duration as well as treatment resistance were assessed retrospectively. When the patient was unable to provide the required data, or when the researcher questioned the reliability of the data provided, the family doctor or treating psychiatrist was consulted to clarify. Since both factors were in the first place assessed retrospectively, their exactness is inherently doubtful and could therefore be considered a limitation of our study. Although we do not expect a major influence of concomitant psychotropics, electrode positions ⁴⁴, anaesthetics used ^{45,46} or the length of the treatment course on ECT effectiveness, the heterogeneity in our treatment protocols should be taken into account when interpreting our results.

Future research

It would be interesting for future research to delineate the role of comorbidity here, particularly personality disorders ⁴¹⁻⁴³, which appear to have a negative impact on the outcome of all forms of depression treatment ^{41,47}. Among other instruments, the Standardized Assessment of Personality – Abbreviated Scale (SAPAS) ^{48,49} may then be used to screen for their presence, most preferably in large samples in order to create a valid prediction model that allows for all relevant clinical variables. **Conclusion**

To conclude, based on the results of our path analysis of the interdependence of predictors (assumed to be) associated with treatment response in depression, ECT can be said to be a very effective option for patients suffering from more severe forms of core depression, which are characterized by either psychomotor agitation or retardation, or psychotic symptoms, or by a combination of these three. However, the chance of a beneficial outcome is reduced in patients with a longer episode duration. In these patients, we suggest to first confirm the diagnosis of depression and to look for comorbidity that may interfere with the response to ECT. Our finding that age merely exerts an indirect influence on ECT outcome is interesting as it suggests that age alone is not a relevant factor when considering ECT.

Clinical points

- Several factors associated with ECT outcome in major depression show substantial entanglement, which makes it hard to distil the most relevant of these factors in order to improve patient-treatment matching.
- When a depressed patients presents with psychomotor or psychotic symptoms, consider ECT.
- We should not base patient-treatment matching on the age of the patient.

References

1. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. *J ECT*. 2004;20(1):13-20. <http://www.ncbi.nlm.nih.gov/pubmed/15087991>.
2. UK ECT Review Group T. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *Lancet*. 2003;361:799-808. doi:10.1016/S0140-6736(03)12705-5
3. Van Diermen L, Van Den Ameele S, Kamperman AM, et al. Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. *Br J psychiatry*. 2018;212(2):71-80. doi:10.1192/bjp.2017.28
4. Husain MM, Rush AJ, Fink M, et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. *J Clin Psychiatry*. 2004;65(4):485-491. <http://www.ncbi.nlm.nih.gov/pubmed/15119910>. Accessed September 9, 2014.
5. Porter ME. What is value in health care? *N Engl J Med*. 2010;363(26):2477-2481. doi:10.1056/NEJMp1011024
6. Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ. Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. *J Clin Psychiatry*. 2015;76(10):1374-1384. doi:10.4088/JCP.14r09528
7. van Diermen L, Vanmarcke S, Walther S, et al. Can psychomotor disturbance predict ect outcome in depression? *J Psychiatr Res*. 2019;117(May):122-128. doi:10.1016/j.jpsychires.2019.07.009
8. Parker G. Classifying depression: should paradigms lost be regained? *Am J Psychiatry*. 2000;157(8):1195-1203. <http://www.ncbi.nlm.nih.gov/pubmed/10910777>. Accessed August 13, 2014.
9. Parker G, Roussos J, Mitchell P, Wilhelm K, Austin MP, Hadzi-Pavlovic D. Distinguishing psychotic depression from melancholia. *J Affect Disord*. 1997;42(2-3):155-167. doi:10.1016/S0165-0327(96)01406-1
10. Parker G, Hadzi-Pavlovic D, Hickie I, et al. Distinguishing psychotic and non-psychotic melancholia. *J Affect Disord*. 1991;22(3):135-148. doi:10.1016/0165-0327(91)90047-V
11. Heijnen WTCJ, Kamperman AM, Tjokrodipo LD, Hoogendijk WJG, van den Broek WW, Birkenhager TK. Influence of age on ECT efficacy in depression and the mediating role of psychomotor retardation and psychotic features. *J Psychiatr Res*. 2019;109:41-47. doi:10.1016/j.jpsychires.2018.11.014
12. van Diermen L, Versyck P, van den Ameele S, et al. Performance of the Psychotic Depression Assessment Scale as a Predictor of ECT Outcome. *J ECT*. 2019;35(4):238-244. doi:10.1097/YCT.0000000000000610
13. van Diermen L, Hebbrecht K, Schrijvers D, Sabbe BCGG, Fransen E, Birkenhäger TK. The Maudsley Staging Method as predictor of electroconvulsive therapy effectiveness in depression. *Acta Psychiatr Scand*. 2018;138(6):605-614. doi:10.1111/acps.12962
14. Sheehan D V., Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry*. 1998;59(suppl 20):22-33. doi:10.1016/S0924-9338(99)80239-9
15. Trajković G, Starčević V, Latas M, et al. Reliability of the Hamilton Rating Scale for Depression: a meta-analysis over a period of 49 years. *Psychiatry Res*. 2011;189(1):1-9.

- doi:10.1016/j.psychres.2010.12.007
16. Kolshus E, Jelovac A, McLoughlin DM. Bitemporal v. high-dose right unilateral electroconvulsive therapy for depression: a systematic review and meta-analysis of randomized controlled trials. *Psychol Med*. 2017;47(3):518-530. doi:10.1017/S0033291716002737
 17. Porter RJ, Douglas K, Knight RG. Monitoring of cognitive effects during a course of electroconvulsive therapy: recommendations for clinical practice. *J ECT*. 2008;24(1):25-34. doi:10.1097/YCT.0b013e31815d9627
 18. Tang VM, Pasricha AN, Blumberger DM, et al. Should Benzodiazepines and Anticonvulsants Be Used during Electroconvulsive Therapy?: A Case Study and Literature Review. *J ECT*. 2017;33(4):237-242. doi:10.1097/YCT.0000000000000441
 19. Petrides G, Fink M. The "half-age" stimulation strategy for ECT dosing. *Convuls Ther*. 1996;12(3):138-146. <http://www.ncbi.nlm.nih.gov/pubmed/8872401>. Accessed November 21, 2014.
 20. Caldieraro MAK, Baeza FLC, Pinheiro DO, Ribeiro MR, Parker G, Fleck MP. Clinical differences between melancholic and nonmelancholic depression as defined by the CORE system. *Compr Psychiatry*. 2013;54(1):11-15. doi:10.1016/j.comppsy.2012.05.012
 21. Parker G, Hadzi-Pavlovic D. *Melancholia: A Disorder of Movement and Mood - A Phenomenological and Neurobiological Review*. (Parker G, Hadzi-Pavlovic D, eds.). Cambridge: Cambridge University Press; 1996. doi:10.1017/CBO9780511759024
 22. Østergaard SD, Meyers BS, Flint AJ, et al. Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. *J Affect Disord*. 2014;160:68-73. doi:10.1016/j.jad.2013.12.020
 23. Østergaard SD, Pedersen CH, Uggerby P, et al. Clinical and psychometric validation of the psychotic depression assessment scale. *J Affect Disord*. 2015;173:261-268. doi:10.1016/j.jad.2014.11.012
 24. Khan A, Khan SR, Shankles EB, Polissar NL. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials. *Int Clin Psychopharmacol*. 2002;17(6):281-285. doi:10.1097/00004850-200211000-00003
 25. Wade BSC, Hellemann G, Espinoza RT, et al. Depressive Symptom Dimensions in Treatment-Resistant Major Depression and Their Modulation With Electroconvulsive Therapy. *J ECT*. 2020;36(2):123-129. doi:10.1097/YCT.0000000000000623
 26. Suzuki A, Aoshima T, Fukasawa T, et al. A three-factor model of the MADRS in Major Depressive Disorder. *Depress Anxiety*. 2005;21(2):95-97. doi:10.1002/da.20058
 27. Cohen J. A power primer. *Psychol Bull*. 1992;112(1):155-159. <http://www.ncbi.nlm.nih.gov/pubmed/19565683>.
 28. Yuan KH, Chan W, Bentler PM. Robust transformation with applications to structural equation modelling. *Br J Math Stat Psychol*. 2000;53 (Pt 1):31-50. <http://www.ncbi.nlm.nih.gov/pubmed/10895521>.
 29. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. *Struct Equ Model A Multidiscip J*. 1999;6(1):1-55. doi:10.1080/10705519909540118
 30. MacCallum RC, Browne MW, Sugawara HM. Power analysis and determination of sample size for covariance structure modeling. *Psychol Methods*. 1996;1(2):130-149.

- doi:10.1037/1082-989X.1.2.130
31. Muthén L, Muthén B. MPlus User's Guide. In: *MPlus User's Guide*. seventh ed. Los Angeles, CA, USA.
 32. Flint AJ, Gagnon N. Effective use of electroconvulsive therapy in late-life depression. *Can J Psychiatry*. 2002;47(8):734-741. doi:10.1177/070674370204700804
 33. Baldwin RC, Jolley DJ. Prognosis of depression in old age. *Br J Psychiatry*. 1987;151:129.
 34. Blazer D. *Epidemiology of Late-Life Depression*. In: *Schneider L Reynolds C Lebowitz B Friedhoff A, Eds. Diagnosis and Treatment of Depression in Late Life*. Washington, DC: American Psychiatric Press; 1994.
 35. Van Diermen L, Schrijvers D, Cools O, Birkenhäger TK, Fransen E, Sabbe BGC. Distinguishing subgroups based on psychomotor functioning among patients with major depressive disorder. *Neuropsychobiology*. 2018;76(4):199-208. doi:10.1159/000490072
 36. Mitchell P, Hadzi-Pavlovic D, Parker G, et al. Depressive psychomotor disturbance, cortisol, and dexamethasone. *Biol Psychiatry*. 1996;40(10):941-950. doi:10.1016/0006-3223(95)00635-4
 37. Maggaard JL, Seeralan T, Schulz H, Brütt AL. Factors associated with help-seeking behaviour among individuals with major depression: A systematic review. *PLoS One*. 2017;12(5):e0176730. doi:10.1371/journal.pone.0176730
 38. Castro-Rodríguez JI, Olariu E, Garnier-Lacueva C, et al. Diagnostic accuracy and adequacy of treatment of depressive and anxiety disorders: A comparison of primary care and specialized care patients. *J Affect Disord*. 2015;172:462-471. doi:10.1016/j.jad.2014.10.020
 39. McIntyre RS, Filteau M-J, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. *J Affect Disord*. 2014;156:1-7. doi:10.1016/j.jad.2013.10.043
 40. Heikman P, Katila H, Sarna S, Wahlbeck K, Kuoppasalmi K. Differential response to right unilateral ECT in depressed patients: impact of comorbidity and severity of illness [ISRCTN39974945]. *BMC Psychiatry*. 2002;2:2. doi:10.1186/1471-244X-2-2
 41. Rasmussen KG. Do Patients With Personality Disorders Respond Differentially to Electroconvulsive Therapy ? A Review of the Literature and Consideration of Conceptual Issues. *J ECT*. 2015;31(1):6-12. doi:10.1097/YCT.0000000000000165
 42. Lee JH, Kung S, Rasmussen KG, Palmer BA. Effectiveness of Electroconvulsive Therapy in Patients With Major Depressive Disorder and Comorbid Borderline Personality Disorder. *J ECT*. 2019;35(1):44-47. doi:10.1097/YCT.0000000000000533
 43. Nordenskjöld A, von Knorring L, Engström I. Predictors of the short-term responder rate of Electroconvulsive therapy in depressive disorders--a population based study. *BMC Psychiatry*. 2012;12:115. doi:10.1186/1471-244X-12-115
 44. Semkovska M, Landau S, Dunne R, et al. Bitemporal Versus High-Dose Unilateral Twice-Weekly Electroconvulsive Therapy for Depression (EFFECT-Dep): A Pragmatic, Randomized, Non-Inferiority Trial. *Am J Psychiatry*. 2016;173(4):408-417. doi:10.1176/appi.ajp.2015.15030372
 45. Lihua P, Su M, Ke W, Ziemann-Gimmel P. Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression. *Cochrane database Syst Rev*. 2014;(4):Art. No: CD009763. doi:10.1002/14651858.CD009763.pub2
 46. Gálvez V, McGuirk L, Loo CK. The use of ketamine in ECT anaesthesia: A systematic

- review and critical commentary on efficacy, cognitive, safety and seizure outcomes. *World J Biol Psychiatry*. 2017;18(6):424-444. doi:10.1080/15622975.2016.1252464
47. Newton-Howes G, Tyrer P, Johnson T, et al. Influence of personality on the outcome of treatment in depression: systematic review and meta-analysis. *J Pers Disord*. 2014;28(4):577-593. doi:10.1521/pedi_2013_27_070
48. Hesse M, Moran P. Screening for personality disorder with the Standardised Assessment of Personality: Abbreviated Scale (SAPAS): Further evidence of concurrent validity. *BMC Psychiatry*. 2010;10:10. doi:10.1186/1471-244X-10-10
49. Ball L, Tully RJ, Egan V. The SAPAS, Personality Traits, and Personality Disorder. *J Pers Disord*. 2016;31(3):385-398. doi:10.1521/pedi_2016_30_259